BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 – a Novel Therapy for GBA1 Parkinson’s Disease

Posted on by

PORTO, Portugal, Jan. 7, 2025 /PRNewswire/ — BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.